NIH-Funded Study Shows Increased Survival in Men with Metastatic Prostate Cancer Who Receive Chemotherapy When Starting Hormone Therapy

Source: National Cancer Institute - Related MedlinePlus Page: Prostate Cancer
Source: MedlinePlus Health News - Category: Consumer Health News Source Type: news

Related Links:

ngione Mario Pulvirenti Antonino Romeo Ugo De Giorgi The therapeutic landscape of prostate cancer has expanded rapidly over the past 10 years, and there is now an even greater need to understand the biological mechanisms of resistance and to develop noninvasive biomarkers to guide treatment. The androgen receptor (AR) is known to be involved in the pathogenesis and progression of prostate cancer. Recently, highly sensitive next-generation sequencing and PCR-based methods for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma were established in cell-free DNA (cfDNA) of patients with c...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Men with advanced prostate cancer who stop responding to targeted hormone therapy but are then treated with modern chemotherapy have better survival rates than those given a second targeted treatment, a study published in the New England Journal of Medicine has shown.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Abstract OBJECTIVE: Docetaxel has been shown to be an effective chemotherapy agent when combined with androgen deprivation therapy for hormone sensitive metastatic prostate cancer (CaP). Since very high risk CaP has a high rate of occult metastatic disease and early recurrence, we hypothesize that patients with very high risk locally advanced CaP may benefit from docetaxel-based neoadjuvant chemohormonal therapy (NCHT). Thus, we conducted a retrospective study to identify the outcome of these patients treated with NCHT followed by radical prostatectomy (RP). PATIENTS AND METHODS: We retrospectively analyzed d...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Abstract We investigated the effectiveness of 11C-choline-positron emission tomography/computed tomography (PET/CT) for evaluating treatment response in patients with prostate cancer or renal cell carcinoma. We performed 34 11C-choline PET/CT scans before/after a combined total of 17 courses of treatment in 6 patients with prostate cancer and 2 with renal cell carcinoma. The 17 treatments including hormonal therapy, radiotherapy, chemotherapy, radium-223, molecular target therapy, radiofrequency ablation, transcatheter arterial embolization, and cancer immunotherapy yielded 1 (5.9%) complete metabolic response (CM...
Source: Acta Med Okayama - Category: Universities & Medical Training Authors: Tags: Acta Med Okayama Source Type: research
This article investigates how Black South Africans residing in Soweto, a township of Johannesburg, perceive and experience breast and prostate cancers amidst multiple, concurrent medical conditions. We used convenience sampling to recruit 80 study participants already enrolled in longitudinal studies of breast and prostate cancers at a tertiary hospital in Soweto between June and August 2017. This included 50 women diagnosed with breast cancer and 30 men diagnosed with prostate cancer; three-quarters of the sample had two or more comorbidities, including HIV, hypertension, diabetes, anxiety, and others. Many described sick...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Authors: Houédé N Abstract To date, systemic treatments, including hormone therapies or chemotherapy, are used at different stages of prostate cancer disease. Several types of complications can occur during systemic treatment in prostate cancer, depending on the therapeutic range. The most common with hormone therapy are fatigue, muscle loss, bone loss, high blood pressure and metabolic syndromes. For chemotherapy, the most significant risk is related to hematological toxicity, but peripheral neuropathies, mucositis, diarrhea and hypersensitivity reactions may also occur. The quality of the pre-treatm...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Authors: Miranda J, Viñal D, Pinto Á Abstract The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the recent years with the approval of several new drugs. Together with other treatment modalities including chemotherapy, hormonal therapy and immunotherapy, radiopharmaceuticals have recently been incorporated to the therapeutic scenario of prostate cancer with the approval of Radium 223 dichloride (Ra-223) for the treatment of mCRPC patients with symptomatic bone metastasis and no visceral metastases. Radiopharmaceuticals have long been used...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Conclusion: Clinical studies in breast cancer patients from Asia have primarily investigated the effect of leuprorelin on the protection of ovarian function in patients who receive chemotherapy, assessed the ability of leuprorelin to suppress serum estradiol to menopausal levels, or to determine the efficacy and safety of leuprorelin in daily medical practice. PMID: 31127911 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Conclusions: 68Ga PSMA PET/CT is a feasible and effective modality for monitoring response to treatment in patients with metastatic disease from prostate cancer post systemic therapy and has a competitive advantage over serum PSA used alone. Discordance between the response on PET/CT based on PET parameters and biochemical response raises the possibility of its true representation of the post-therapy disease burden. It may be used as a guide to planning local therapy in cases with limited disease burden. It is particularly useful in cases with low pre-therapy serum PSA levels. Secondary observations hint its ability to be ...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis II Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hormonal Therapy | Hormones | Prostate Cancer | Study